Natural combination hormone replacement formulations and therapies
US10206932B2 · kind B2 · utility
21Cited by
566References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2015 |
| Grant date | Feb 19, 2019 |
| Priority date | — |
| Expiry date | Aug 8, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.